Stephen Mandel’s Amicus Therapeutics FOLD Stock Holding History

Stephen Mandel’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-6,678,788	Closed	-$154M	–	42
2020 Q4	$154M	Buy	+6,678,788	New	+$137M	0.56%	35

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Stephen Mandel's FOLD Position: Q1 2021 in Review

Stephen Mandel sold out of Amicus Therapeutics (FOLD) in Q1 2021, closing a stake of 6,678,788 shares — an estimated $154M sold.

Stephen Mandel first reported a position in FOLD in Q4 2020 and held it in 1 quarter. The position peaked at $154M in Q4 2020. 259 funds tracked by Wall St. Rank hold FOLD as of Q1 2021.

Stephen Mandel reported no remaining Amicus Therapeutics position as of Q1 2021 after selling out during the quarter.
Stephen Mandel sold 6,678,788 Amicus Therapeutics shares in Q1 2021, an estimated $154M.
Stephen Mandel first reported a position in Amicus Therapeutics in Q4 2020 and held it in 1 quarter.
Stephen Mandel's Amicus Therapeutics position peaked at $154M in Q4 2020.
259 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2021.

Based on Lone Pine Capital's 13F filing for Q1 2021, filed 18 May 2021.